Format

Send to

Choose Destination
J Hematol Oncol. 2013 Apr 12;6:27. doi: 10.1186/1756-8722-6-27.

MEK and the inhibitors: from bench to bedside.

Author information

1
Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA. DELONG_LIU@NYMC.EDU.

Abstract

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.

PMID:
23587417
PMCID:
PMC3626705
DOI:
10.1186/1756-8722-6-27
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center